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ABSTRACT 
J. Makenzie Nutter. INTERRELATED ROLE OF NOTCH SIGNALING AND mTORC 
PATHWAYS IN PROSTATE CANCER CELL SURVIVAL AND GROWTH. (Under the 
direction of Dr. Fred E. Bertrand). Department of Oncology, July 2014. 
 
Prostate cancer is currently the second highest leading cause of cancer death in men. 
Notch is a transmembrane receptor protein that is part of a signaling pathway necessary 
in the normal development of the prostate. Notch1 signaling has been shown to be lost 
in prostate adenocarcinoma. One of prostate cancer’s biggest risk factors is age and 
mTOR has been shown to be linked to longevity and age related diseases. mTOR 
exists as two complexes, mTORC 1/2, whose key functions are to control cell survival, 
metabolism, and growth. mTORC1/2 are often overexpressed in cancer. It was also 
reported that the mTORC1 pathway became inactivated when Notch1 signaling was 
inhibited in prostate cancer cell line PC-3. Herein, we suggest a link between Notch1 
signaling and mTOR pathway activity which led to experiments with DU145 cells 
manipulated to have decreased Notch1 expression. The data shows that loss of Notch1 
signaling causes decreased expression of the mTORC1 component Raptor as well as 
decreased phosphorylation of mTORC1 downstream target 4E-BP1 in conditions of cell 
stress. The mTORC2 pathway exhibited decreased phospho-mTOR (Ser2481) in 
normal conditions and decreased Rictor signaling in both normal and serum starved 
conditions when Notch1 expression was lost. The data also suggests there is less GβL 
in conditions of stress in Notch1 knockdown cells. We hypothesize that downregulation 
of Notch1 signaling leads to the dysfunction of both mTOR pathways. 
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CHAPTER 1 
INTRODUCTION 
Prostate cancer is the second leading cause of cancer related deaths in men in 
the United States (Siegel et al, 2013). It is estimated 1 in 6 men will get prostate cancer 
in their lifetime, with 6 in 10 men at risk for the cancer once over the age of 65. Various 
therapies exist now such as chemotherapy that are successful in treating primary 
prostate cancer still in the organ, but the main issue that accounts for such a high 
mortality rate is that tumors tend to progress to metastatic cancer which currently has 
no curative therapies (Wang et al., 2010). 
In the past few decades, research has arisen showing that Notch signaling has a 
role in how cancers function. Notch was initially discovered as a gene that caused a 
“notch” in the wings of Drosophila melanogaster (Shellenbarger and Mohler, 1975). It is 
well understood now that Notch is a transmembrane heterodimeric receptor protein 
family of four, called Notch1/2/3/4. A human Notch homolog was first documented in 
1991 in a case of T-cell acute lymphoblastic leukemia (T-ALL) in which a chromosomal 
translocation caused a truncated form of Notch that was constitutively active. It was 
originally called translocation-associated Notch-1 homolog, or TAN-1 (Ellisen et al., 
1991). 
Notch is conserved in many species. In mammals, Notch has five ligands: 
Jagged1/2 and Delta-like 1/3/4 (Dll1/3/4) (Fleming, 1998). When a Notch receptor on 
one cell binds to its ligand on an adjacent cell, a conformation change occurs. This 
stimulates a series of cleavage events. The conformational change in the Notch 
receptor reveals an S2 cleavage site that tumor necrosis factor-α converting enzyme 
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(TACE) will cleave in the Notch extracellular domain (Mumm and Kopan, 2000). Directly 
after, S3 cleavage occurs within the Notch transmembrane domain by the γ-secretase 
complex which consists of presenelin-1/2, nicastrin, Pen-2, and Aph-1 (Edbauer et al., 
2003). The Notch intracellular domain (NICD) is released into the cytoplasm and can 
then translocate to the nucleus (Struhl, 1998). 
Once inside the nucleus, the NICD will bind to the transcriptional repressor C 
protein binding factor 1/Suppressor of Hairless/Lag1 (CSL) which converts it to a 
transcriptional activator (reviewed in Leong and Gao, 2008). This can be seen in Figure 
1.1. Notch signaling is therefore responsible for directing expression of its downstream 
target Hairy/Enhancer of Split 1 (HES1). HES1 is from a family of basic helix loop helix 
transcription factors that acts as a transcriptional repressor when activated by Notch 
(Iso et al., 2003). 
Normal Notch signaling is crucial for cell differentiation, proliferation and growth. 
Notch signaling is also critical for postnatal tissue development and adult tissue 
maturation, and serves as a key regulator of normal prostate development (Artavanis et 
al., 1999; Wang et al., 2006). The function of Notch in cancer has been shown to have 
both an oncogenic and a tumor suppressive role. Overexpressed Notch1 receptor 
signaling has been observed in cancers such as T-ALL (Ellisen et al., 1991), B-cell 
derived Hodgkin lymphoma (Jundt et al., 2002), and in solid tumors of the brain, cervix, 
pancreas, and breast (Leong, 2006). A tumor suppressive role for Notch1 signaling has 
been seen mainly in skin as well as neuroendocrine tumors such as carcinoids (Nicolas 
et al., 2003; Kunnimalaiyaan et al, 2005). It is clear from the various reports that Notch 
signaling varies between two crucial functions among cancers. More research is critical 
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to understanding how Notch functions for cancers such as prostate cancer with high 
diagnosis and mortality rates. However, it is not clearly understood if Notch promotes or 
inhibits tumorigenesis in the prostate. 
Loss of phosphatase and tensin homolog (PTEN) expression and/or function is 
observed in up to 60% of clinical prostate cancer cases (Li et al., 1997). PTEN is a 
tumor suppressor gene that has been shown to be regulated by Notch1 signaling, in 
that PTEN gene expression goes up when Notch1 signaling is overexpressed (Chappell 
et al., 2005; Whelan et al., 2009). PTEN has three known functions, as a lipid 
phosphatase (Maehama and Dixon, 1998), a protein phosphatase (Li et al., 1997; 
Myers et al., 1997), and a phosphorylation substrate (Torres et al., 2003). Most 
commonly, PTEN is known as a negative regulator of the proto-oncogenic 
phosphoinositide (PI) 3-Kinase/Akt pathway. 
Briefly, PTEN functions as a lipid phosphatase to target active phosphatidyl 
inositol 3,4,5-triphosphate (PIP3) and remove the phosphate at the 3’ position of the 
inositol ring, converting it to the inactive precursor PIP2 so that downstream signaling to 
other pro-survival effector proteins like Akt is prevented (reviewed in Paez and Sellers, 
2003). The PI3-K/Akt pathway normally exerts survival and proliferative signals in cells 
when not bound to PTEN (Salmena et al., 2008). When PTEN is lost in cancers, this 
allows for constitutive activation of the PI3-K/Akt pathway which helps the cancer cells 
survive and grow (Vivanco & Sawyers, 2002). 
Along with the dysregulation of the PI3-K/Akt pathway, the mammalian target of 
rapamycin (mTOR) is often overexpressed in cancer (Alvarez et al., 2003; Yu et al., 
2009). mTOR is a protein Ser-Thr kinase involved in the control of cell growth and  
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Figure 1.1: Notch signaling pathway.  Upon binding to a ligand from an adjacent cell, 
the Notch receptor undergoes two cleavage events. The first cleavage event, known as 
S2, is performed by an ADAM metalloprotease called TACE which cleaves the 
extracellular portion of the Notch receptor. S3 cleavage then occurs using the γ-
secretase complex which cleaves in the intermembrane to release the Notch 
intracellular domain (NICD) which can then translocate to the nucleus, bind to the 
transcriptional repressor CSL, and allow transcription to occur. 
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proliferation (Harris et al., 2003). mTOR exists as two distinct complexes with very 
distinct functions. mTOR complex 1 (mTORC1) forms when mTOR, Raptor (regulatory 
associated protein of TOR) and GβL (also known as LST8) join together (Jacinto & Hall, 
2003). mTORC1 has the ability to phosphorylate downstream targets that are necessary 
for translation to occur and activation of this pathway ultimately leads to protein 
synthesis and cell growth, seen in Figure 1.2. 
mTOR complex 2 (mTORC2) was discovered in 2004 and forms a complex with 
mTOR, Rictor (rapamycin insensitive component of TOR), and GβL (Sarbassov et al., 
2004). Its functions have not been clearly defined, but it is now understood that 
mTORC2 plays a role in cytoskeleton formation (Jacinto et al., 2004) and in 
phosphorylation of Akt at Serine 473 (Sarbassov et al., 2005). This particular 
phosphorylation of Akt at Ser473 is not necessary for normal functioning. Akt plays an 
important role in the mTOR pathways in that it both affects and is affected by mTOR 
depending on which complex is formed and functional. 
mTOR is a nutrient and metabolic sensor that is activated when nutrients and 
growth factors, such as insulin, are readily available (Fingar & Blenis, 2004). When 
nutrients are present, the PI3-K/Akt pathway activates. Akt will phosphorylate and 
inactivate the tuberous sclerosis complex 1 (TSC1) which is a tumor suppressor 
responsible for suppressing mTOR activity (Gao et al., 2002, Inoki et al., 2002). From 
here, mTORC1 can go on to phosphorylate its downstream targets 4E-BP1 (Graves et 
al., 1995) and p70 S6 kinase (S6K) (Chung et al., 1992). In the case of 4E-BP1, 
phosphorylation from mTOR causes it to bind less tightly to its target elF4E (Lin et al., 
1994) which allows elF4E to form complexes important for cap-dependent translation 
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(Beretta et al., 1996). mTORC1 mediated phosphorylation of p70 S6K has several 
translational control functions which include positively regulating helicase activity 
(Shahbazian et al., 2006) and enhancing translation of newly spliced mRNAs (Ma et al., 
2008). 
Much less is known about mTORC2. Recent data has suggested very specific 
roles for it in both prostate cancer upon loss of PTEN in mice (Guertin et al., 2009) and 
in regulating glucose metabolism with a suggested role in the development of type II 
diabetes (Kumar et al., 2008). Its most well-known roles are in cytoskeleton formation 
and specific, but not necessary for function, phosphorylation of Akt at Ser473. However, 
it is still not clear what upstream regulators there are for this pathway. Several studies 
recently however have suggested Notch signaling plays a specific role in mTOR 
functions. 
 Knockdown of Notch1 and its ligand Jagged1 in the prostate cancer cell line PC-
3 has been shown to inhibit prostate cancer cell growth and lead to apoptosis due to 
inactivation of the Akt and mTOR pathways (Wang et al., 2010). Another study has 
shown that mTOR regulates cell differentiation by serving as a positive regulator of 
Notch signaling (Ma et al., 2010). A study on mutant T-ALL cells showed that by 
inhibiting PI3-K/mTOR pathways, Notch signaling was increased and that there was 
Notch induced resistance to PI3-K/mTOR inhibition (Shepherd et al., 2013). These have 
important implications of the treatment of cancers and diseases with overexpressed 
Notch signaling with use of combinational Notch/mTOR inhibitor drug therapies. 
In this present study, Notch1 signaling was knocked down in DU145 metastatic 
prostate tumor cells. These cells, called DU/shN1, were used to examine the effects of 
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Notch1 loss on the mTOR pathways. Loss of Notch1 resulted in decreased expression 
of downstream target S6 ribosomal protein and in phosphorylation of 4E-BP1 in both 
normal and serum starved conditions. Loss of Notch1 expression also played a role in 
decreasing mTOR signaling through decreased expression of the key complex 
components Raptor and Rictor. The data also suggests there is less GβL in conditions 
of stress in Notch1 knockdown cells. 
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Figure 1.2: mTOR signaling pathway. When PI3-K is activated, it will phosphorylate 
Akt at Thr308. Phosphorylated Akt binds and deactivates TSC1/2. TSC1/2 can no 
longer repress mTOR signaling and the complexes can form. mTOR complex 1 is 
phosphorylated at Ser2448 and will phosphorylate 4E-BP1 to inactivate it and p70 S6 
Kinase to activate it, both of which events lead to cell proliferation and growth. mTOR 
complex 2 is phosphorylated at Ser2481 and can affect actin cytoskeleton formation 
and also loop back to phosphorylate Akt at Ser473 which helps to maintain Akt activity. 
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CHAPTER 2 
METHODS 
 Cell lines 
DU145 cells were purchased from the ATCC. DU145 cells were originally derived from 
brain metastasis of a prostate cancer patient, and are thus considered representative of 
metastatic prostate cancer (Stone et al., 1978). Cells were maintained in RPMI 
supplemented with 10% heat inactivated fetal bovine serum (FBS) (Cellgro; Herndon, 
VA) at 37° C with 5% CO2, penicillin (10 units/ml), and streptomycin (10 µg/µl) 
(Invitrogen; Carlsbad, CA). The stable transformed cell lines, DU PLK 1.0 and DU/shN1, 
were maintained as described above and also treated with puromycin (2 µg/ml) (Sigma; 
St. Louis, MO). For serum starved cells, 1.5 x 106 parental DU145, DU PLK 1.0, or 
DU/shN1 cells were plated on tissue culture plates in complete RPMI medium and 
cultured for 6 hours. Next, media was removed and cells were rinsed twice with 
phosphate buffer saline (PBS) and cultured in serum free RPMI. Cells were incubated 
overnight and harvested 16 hours later for protein analysis. For insulin treatment, cells 
were serum starved as described above and before harvesting were treated with bovine 
insulin (2 µl/10ml) (Sigma; St. Louis, MO) and incubated for 10 minutes before being 
harvested for protein collection. 
 Lentiviral packaging 
shRNA lentiviral constructs against Notch1 were purchased from Open Biosystems 
(Lafayette, CO). Lentiviruses were packaged per manufacturer’s instructions. Briefly, 
viral constructs were packaged with an amphotropic coat in 293 cells. Forty eight hours 
post-transfection, viral supernatant was collected and used to transduce DU145 cells. 
Transduced DU145 cells were selected in 2µg/ml of puromycin. 
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 Cell Dividing Time assay 
Two hundred thousand cells from the following cell lines were plated into individual cell 
culture plates containing complete RPMI: DU145, DU PLK 1.0, and DU/shN1. After 96 
hours, the cells were fully trypsinized and counted with a hemacytometer to determine 
the total number of cells in the plate. The duplication time was calculated using the 
following formula: d=t*Ln(2)/Ln(Nt/N0) where Nt is the number of cells at the time of 
counting, N0 is the initial amount of cells, t is the hours of growth, and d is the 
duplication time in hours. 
Western blot analysis 
Total cell lysate protein was quantitated based on cell number and prepared in 1 ml 
RIPA lysis buffer per 3 million cells. Lysates were stored at -80° C. Twenty µl of total 
cellular protein from each sample was loaded per well and separated on 8% or 12% 
SDS-PAGE gels, transferred to PVDF membranes, and blocked in 1% bovine serum 
albumin (BSA) at room temperature for 1 hour. Blots were probed with primary 
phospho-specific antibodies (1:1000 dilution in 1% BSA) or total protein recognizing 
antibodies (1:1000) overnight at 4° C, and either β-tubulin (hybridoma) or β-actin 
(1:5000) as loading controls. Horseradish peroxidase (HRP) conjugated secondary 
antibodies (anti-rabbit or –mouse) diluted (1:5000) in TBST (25mM Tris-HCl [pH 8.0], 
125mM NaCl, 0.02% Tween-20) were used to detect protein-bound primary antibody. 
Horseradish peroxidase chemiluminescence substrate (Pierce; Rockfield, IL) and 
radiography film were used to visualize protein bands. All primary antibodies can be 
found in Table 2.1. 
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Table 2.1: Primary Antibodies 
Antibody Name Company Catalog # 
mTOR Cell Signaling 2972 
p-mTOR (Ser2448) Cell Signaling 5536 
p-mTOR (Ser2481) Cell Signaling 2974 
Notch1 (D6F11) Cell Signaling 4380 
Akt (pan) (11E7) Cell Signaling 4685 
p-Akt (Ser473) (D9E) Cell Signaling 4060 
4E-BP1 (53H11) Cell Signaling 9644 
p-4E-BP1 (Thr37/46) Cell Signaling 2855 
S6 Ribosomal Protein Cell Signaling 2217 
Raptor (24C12) Cell Signaling 2280 
Rictor (53A2) Cell Signaling 2114 
p-Rictor (Thr1135) Cell Signaling 3806 
 
Transwell migration assay 
Transwell inserts (Costar; Corning, NY) were placed in a 24 well plate, with three 
transwells for each cell line for each experiment. Cells were washed with PBS then 
brought up in serum free RPMI media to a dilution of 1 x 106 cells/ml. Then, 100µl was 
added to the top of the transwells and incubated for ten minutes at 37° C. A stock of 
RPMI with 20% serum was made and at the end of the incubation period, 600 µl of the 
stock was added to the bottom of each transwell chamber to serve as a chemoattractant 
for the cells. The 24 well plate was then incubated overnight at 37° C. The next day, 
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cells were removed from the top layer of the transwells and fixed in 70% ethanol for ten 
minutes then removed and allowed to dry for five minutes. Cells were then placed in 
0.2% crystal violet for ten minutes to stain cells that had migrated through the transwell 
membrane. Transwells were then washed in dH2O and allowed to dry before counting. 
 
  
CHAPTER 3 
RESULTS 
Generation of DU145 cells with decreased expression of Notch1. In order to study 
the effects of loss of Notch1 on the mTOR complexes, we generated DU145 cells that 
stably express a shRNA to abrogate Notch1 expression (DU/shN1) as well as DU145 
cells that express the empty vector alone (DU PLK 1.0). Stably transfected cells were 
isolated using puromycin treatment with every cell passage due to the vector containing 
a gene that confers puromycin resistance to the cells. Loss of Notch1 was verified by 
Western blot analysis using an anti-Notch1 antibody (Cell Signaling), seen in Figure 3.1. 
DU/shN1 cells have slower dividing time and decreased migratory ability. A cell 
dividing time assay was conducted as previously described to determine if there were 
any differences due to down regulation of Notch1. Three experiments were run on each 
cell line. On average, DU/shN1 cells were at least three hours slower to divide than DU 
PLK 1.0 cells and at least four hours slower to divide than DU145 cells, seen in the 
chart in Figure 3.2A. A student t-test confirmed these differences were not statistically 
significant. 
Transwell migration assays were also performed as previously described to test 
migratory ability of cells with knockdown of Notch1. Results indicate that DU/shN1 cells 
have a significantly decreased ability to migrate when compared to DU145 and DU PLK 
1.0 cells, which can be seen in the chart of Figure 3.2B. Statistical significance was 
determined by student t-test. 
Downregulation of Notch1 causes no change in mTOR expression. Due to the 
reduction in cell dividing time and migratory ability when Notch1 expression was 
reduced, we next examined the mTOR pathway. Figure 3.3 shows the results of  
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Figure 3.1: Establishment of stable Notch1 knockdown DU145 cells. A) Lentiviral 
constructs. The constructs used are lentiviral constructs in which shN1 contains the 
silencer for downregulating Notch1 signaling and PLK 1.0 is the empty vector control. 
Constructed DU/shN1 and DU PLK 1.0 cells were purified using puromycin as 
previously described which was included in the vector constructs. B) Confirmation of 
Notch1 knockdown. Stable knockdown of Notch1 signaling was confirmed by Western 
blot. 
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Figure 3.2: DU/shN1 cells have slower dividing time & decreased migratory 
ability. A) Cell Dividing Time. The chart lists the results of three consecutive cell 
dividing time assays for all three cell lines. DU/shN1 cells on average grew four hours 
slower than DU145 control cells and three hours slower than the DU PLK 1.0 vector 
control cells. Student t-tests reveal these are not statistically significant differences. B) 
Migration Assay. Three migration assay sets of three wells per cell line were 
performed. The (*) denotes a statistically significant decrease in migratory ability of 
DU/shN1 cells from DU145 cells as determined by a T-test where a p value less than 
0.05 is considered statistically significant. Avg. = Average, St. Dev. = Standard 
Deviation, S.E. = Standard Error 
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Notch1 knockdown on total mTOR expression. No significant differences in total mTOR 
expression were observed between cell lines in either control conditions or serum 
starved conditions. 
Downstream targets of mTORC1 show altered signaling in DU/shN1 cells in 
serum starved conditions. Downstream targets of mTORC1 were next observed to 
see if the changes in cell growth and migratory ability were due to components 
responsible for translation in Notch1 knockdown cells. Results in Figure 3.4A show p-
4E-BP1 expression was decreased in DU/shN1 cells in the serum starved condition, 
suggesting that cells without Notch1 expression are more sensitive to nutrient 
deprivation through the mTOR pathway. In Figure 3.4B, results show that total S6 
ribosomal protein decreases in DU/shN1 cells when compared to both controls, 
although there appears to be a modest decrease in DU PLK 1.0 cells as well. Due to the 
observed evidence that mTOR signaling may be decreased as seen in a reduction of p-
4E-BP1, we examined the phosphorylation status of mTOR which is required for 
complex assembly and expression of Raptor and Rictor, key components of mTORC1 
and mTORC2, respectively. 
Expression of mTORC1&2 complex components, Raptor and Rictor, is reduced in 
DU/shN1 cells. Figure 3.5A shows the results of Notch1 knockdown on the mTORC1 
pathway components. Although phosphorylation of mTOR at Ser2448, which is 
generally a mTORC1 specific site, remains the same, there is a reduction of Raptor 
expression upon serum starvation of DU/shN1 cells. This loss of a necessary 
component to the complex could lead to the dysregulation of mTORC1’s downstream 
targets. However, there also appears to be a decrease of Raptor expression in DU145  
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Figure 3.3: Loss of Notch1 causes no changes in mTOR expression. Cells were 
lysed in normal conditions and serum starved overnight conditions to test if the mTOR 
expression was decreased at any point when Notch1 signaling was knocked down. 
There were no differences in expression levels between cells in either condition. 
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cells when compared to DU PLK 1.0 cells, so the degree to which Notch1 is involved is 
less clear. For mTORC2, the results seen in Figure 3.5B show that both mTOR 
phosphorylated at Ser2481, an mTORC2 specific site, and Rictor have decreased 
signaling in normal conditions. In serum starved conditions, it appears that mTOR 
overexpresses phosphorylation at Ser2481, but Rictor expression remains reduced. 
These results can also explain reduced mTOR signaling, through reduction of Rictor 
and failure to form the mTORC2 complex. 
Preliminary data shows a decrease in GβL, a key component to both the mTORC1 
and mTORC2 complex, in DU/shN1 cells. GβL is a key component in the formation of 
both mTOR complexes, and is lost in DU/shN1 cells in starved + insulin conditions. This 
result also needs to be further studied, as there is less in DU145 cells than in DU PLK 
1.0 cells. This result can be seen in Figure 3.6. 
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Figure 3.4: mTORC1 mediated phosphorylation of downstream targets decreased 
in Notch1 knockdown cells in serum starved conditions. A) Total 4E-BP1 
expression is marginally increased in DU/shN1 cells in serum starved conditions when 
compared to controls. This result is confirmed in that there is a loss of phosphorylated 
4E-BP1 in Notch1 knockdown cells in starved conditions. B) Total S6 ribosomal protein 
signaling is lost in DU/shN1 cells in serum starved conditions when compared to both 
controls. 
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Figure 3.5: Downregulation of Notch1 causes dysregulation of both mTOR 
complexes’ components. A) Loss of Notch1 causes decreased Raptor expression 
in conditions of cell stress. Raptor expression is lost in Notch1 knockdown cells in 
serum starved conditions. B) Decreased Notch1 correlates with decreased Rictor 
expression in normal and serum starved conditions.  In normal conditions, DU/shN1 
cells have decreased phosphorylation of mTOR at Ser2481 when compared to both 
controls although differences in expression when compared to DU145 cells appear 
minimal. In normal conditions, Rictor expression is also reduced in DU/shN1 cells. Upon 
serum starvation, phosphorylation of mTOR at Ser2481 increases but Rictor expression 
still remains less active when compared to controls. 
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Figure 3.6: Preliminary data reveals a decrease in GβL expression in serum 
starved + insulin condition of DU/shN1 cells. GβL has decreased expression in 
Notch knockdown cells in starved + insulin conditions when compared to both controls, 
although there is a slight decrease in expression in DU145 cells when compared to DU 
PLK 1.0 cells. 
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CHAPTER 4 
DISCUSSION 
 To further examine the interaction between Notch1 signaling and the mTOR 
pathways, the human metastatic prostate cancer cell line DU145 was transduced with a 
shRNA lentivirus to reduce Notch1 expression (DU/shN1). DU145 cells were also 
transduced with a control vector (DU PLK 1.0). Notch1 knockdown was verified by 
Western blot analysis. Initial observations of the newly transfected cell lines 
demonstrated that Notch1 knockdown resulted in a slower cell dividing time and a 
decreased ability to migrate. Changes to cell morphology were not observed. These 
results led to the hypothesis that loss of Notch1 signaling was inhibiting a pathway 
responsible for cell growth and proliferation. 
mTOR is commonly overexpressed in cancer. mTOR is responsible for 
controlling cell growth and proliferation. Current research suggests that there is a link 
between Notch signaling and mTOR in cancers (Wang et al., 2010; Shepherd et al., 
2013), although the precise mechanism is not clearly understood. By knocking Notch1 
expression down, our findings indicate mTOR loses some degree of functionality. 
The effects of downregulated Notch1 on mTOR are intriguing. Although there is 
no change in total mTOR expression, expression of the mTORC2 component Rictor is 
reduced. Most of the disrupted signaling is seen in conditions of cell stress due to serum 
starvation. Serum starving cancer cells in vitro is a way to mimic metabolically stressed 
cells in vivo to see how they adapt to a new environment (Levin et al., 2010). Adaptation 
is an important characteristic of cancer cells, for without it the cells would not be able to 
survive or metastasize. Serum starvation may also serve as a way to “prime” cells for 
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death (Braun et al., 2011). Stress in a cell induces activation of many survival pathways 
in order to restore the cell’s health, yet these pathways must be controlled to prevent 
aberrant effects. 
When Notch1 signaling is lost, there is a decrease in expression of Raptor, 
phospho-4E-BP1, and S6 ribosomal protein under serum starvation. However, the fact 
that mTOR expression remains the same suggests that Notch1 does not play a role in 
mTOR directly but with its components. The fact that the downstream targets of 
mTORC1 also have decreased expression indicates that the complex is disrupted. 
There is a decrease of phosphorylation of 4E-BP1 seen in DU/shN1 cells in 
starved conditions when compared to either control. This loss of phosphorylation by the 
mTOR complex allows for 4E-BP1 to remain active and prevent cap dependent 
translation (Beretta et al., 1996). In the case of p70 S6 kinase, the other downstream 
target of mTORC1, this research was unable to see it on a Western and instead looked 
at p70 S6 kinase’s direct downstream target S6 ribosomal protein. Results show there is 
a loss of total S6 protein signaling in starved conditions of DU/shN1 cells. Without S6 
protein, several translational control functions may be lost, as mentioned previously. 
A decrease in cell growth is seen in the cell growth assays in which DU/shN1 
cells have slower growth rates than both DU145 and DU PLK 1.0 cells, although t-test 
shows that these are not statistically significant differences. Cells also have a 
decreased migratory ability as seen by the transwell migration assays which do have 
statistical significance. The results of both assays support a disruption in mTOR 
complex formation. 
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A preliminary look into GβL shows a very interesting result. It appears that in 
conditions of serum starvation plus addition of insulin, there is no detectable expression 
of GβL in DU/shN1 cells. Preliminary probing of GβL expression in normal and serum 
starved conditions are inconclusive at this time. Further investigation is needed to 
confirm this result, but it would explain why both mTOR complexes are not functioning 
correctly, in that it is a key component to both mTOR complexes. 
A study in 2009 showed that Notch1 signaling played a non-canonical role in 
activating mTORC2 in HeLa cells. This was believed to activate an anti-apoptotic 
pathway when cells underwent stress due to serum starvation (Perumalsamy et al., 
2009). This paper would be consistent with the findings that Notch signaling is 
overexpressed in many types of cancer. The more Notch signaling, the less likely a 
cancer cell is to die during its metastatic phase or when treated with chemotherapeutic 
drugs. Those studies are consistent with our findings in that as we lose Notch signaling 
we observe tumor suppressive effects. 
All of these results lead to a very interesting potential for new combinational drug 
therapy for prostate cancer. This research suggests that when Notch1 signaling is 
knocked down, DU/shN1 cells lose migratory ability and have a slower growth rate. The 
changes in the mTORC2 pathway when Notch1 is decreased are especially intriguing 
because there is currently very little literature in what are upstream effectors of this 
specific pathway. There are drugs currently available used to inhibit both Notch and 
mTORC1 signaling individually to treat cancer. It may be possible to treat with both a 
mTOR inhibitor and Notch inhbitor, in which both mTORC1 and Notch are inhibited. If 
Notch1 truly is an upstream effector of mTORC2, mTORC2 signaling will be knocked 
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out as well and cancer cells will lose an entire major pathway responsible for growth 
and survival. Further research is needed to test the hypothesis that Notch-1 may be an 
upstream effector of mTORC2. 
Figure 4.1 proposes a simplified model of what we believe the research is 
showing. Notch1 signaling has already been suggested to play a role in regulating 
PTEN which serves as a key component in the PI3-K/Akt/mTOR survival pathway. In 
most prostate cancers, PTEN function is lost and therefore the PI3-K/Akt/mTOR 
pathway is activated and can lead to uncontrollable cell growth and proliferation. Herein, 
we suggest that there is a very specific balance to Notch1 signaling in prostate cancer. 
Previous research has suggested that overexpression of Notch1 in DU145 cells causes 
an increase in PTEN expression which would have a tumor suppressive effect, but this 
research shows that significant loss of Notch1 also has a tumor suppressive effect in 
the DU145 cell line. 
In our model, Notch signaling and PTEN are signaling low enough to the point 
that the PI3-K/Akt/mTOR pathways still function. When Notch1 signaling is further 
decreased, mTOR complex formation is negatively impacted and mTORC1 loses most 
of its kinase functions to the extent cell growth is slowed and migratory ability is 
lessened. Further studies should be performed to look into the loss of GβL and its link to 
Notch signaling. 
A proposed experiment for future research in this area would be to look at DU145 
cells treated with Notch and mTOR signaling inhibitors in combination as well as 
individually. Looking at individual and combined treatment would allow for us to see if 
there are differences in cell death rate and how the mTOR pathways change based on 
 34 
 
the drug treatment. If Notch1 is a true effector of the mTORC2 pathway directly, it could 
be the key to knocking out the entirety of one of the most overexpressed pathways in 
prostate cancer. 
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Figure 4.1: Proposed Notch signaling model. This simplified model shows the 
suggested role of Notch signaling in prostate cancer. On the right hand side, Notch 
plays a role in maintaining inactive PTEN so that the PI3-k/Akt/mTOR pathway is active 
and this leads to cell growth, proliferation, translation, and survival through the 
mTORC1 pathway. When Notch1 expression is lost, Notch plays a role in mTOR 
complex formation to the extent mTORC1 loses some kinase activity, especially in 
serum starved conditions. 
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